NASDAQ: CGEMCullinan Therapeutics Inc Stock
$6.91-0.81 (-10.49%)
Updated Sep 4, 2025
CGEM Price
$6.91
Fair Value Price
$1.50
Market Cap
$407.79M
52 Week Low
$6.61
52 Week High
$18.62
P/E
-2.6x
P/B
0.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$178.74M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$150M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGEM Overview
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CGEM's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CGEM
Ranked#474 of 481
Ranked#474 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.05 | A | |
| $40.13 | A | |
| $12.53 | A |
Be the first to know about important CGEM news, forecast changes, insider trades & much more!
CGEM News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CGEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGEM ($6.91) is overvalued by 359.54% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CGEM ($6.91) is not significantly undervalued (359.54%) relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CGEM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CGEM due diligence checks available for Premium users.
Valuation
CGEM fair value
Fair Value of CGEM stock based on Discounted Cash Flow (DCF)
Price
$6.91
Fair Value
$1.50
Overvalued by
359.54%
CGEM ($6.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGEM ($6.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGEM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGEM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.6x
Industry
-105.96x
Market
35.52x
CGEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
4.66x
CGEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGEM's financial health
Profit margin
Revenue
$0.0
Net Income
-$48.5M
Profit Margin
0%
CGEM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$579.7M
Liabilities
$27.8M
Debt to equity
0.05
CGEM's short-term assets ($317.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGEM's short-term assets ($317.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$43.2M
Investing
$36.8M
Financing
$0.0
CGEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGEM vs Biotech Stocks
Cullinan Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.